A Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma

Conditions

Melanoma, skin

Phase I

Volunteers
Health Professionals

What is the purpose of this trial?

This study is a Phase 1, open-label, single institution, dose escalation and dose expansion study to evaluate the efficacy, safety, and tolerability of APX005M in combination with nivolumab and ipilimumab in patients with advanced melanoma and RCC.

Find out more about who can participate in this trial

Trial with
Yale Cancer Center
Start Date
05/16/2022
End Date
08/31/2024

For more information about this study, contact:

Barbara Johnson

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Harriet Kluger, MD
Professor of Medicine (Medical Oncology); Director, Yale SPORE in Skin Cancer, Yale Cancer Center; Director, Yale Immuno-Oncology Training Program; Harvey and Katherine Cushing Professor of Medicine and Dermatology, Internal Medicine; Associate Cancer Center Director, Education, Training and Faculty Development; Deputy Section Chief, Medical Oncology

Sub-Investigators

Last Updated
05/20/2022
Study HIC
#2000026830

A Phase I Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information